# A Study of LP-118 in Patients With Advanced Tumors

> **NCT05025358** · PHASE1 · COMPLETED · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 68 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** LP-118 tablet

## Key facts

- **NCT ID:** NCT05025358
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-08
- **Primary completion:** 2025-07-09
- **Final completion:** 2025-07-09
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025358, "A Study of LP-118 in Patients With Advanced Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05025358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*